SCHEMBL3901138

SCHEMBL3901138

Cc1cccc(C(=O)NC(c2ccccc2)C(C)(C)N(C)C)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 2/20 0.41
ITGB1 P05556 1/20 0.41
ITGA4 P13612 1/20 0.41
LMNA P02545 4/20 0.41
GPR139 Q6DWJ6 1/20 0.40
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TAS1R3 Q7RTX0 2/20 0.39
TAS1R1 Q7RTX1 2/20 0.39
TAS1R2 Q8TE23 2/20 0.39
HPGD P15428 2/20 0.38
SLC6A9 P48067 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TRPM8 Q7Z2W7 1/20 0.37
P2RX7 Q99572 2/20 0.37
CTSS P25774 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3907125 0.89 TAS1R3 (0.51) LMNAGPR139SMN1; SMN2TAS1R3TAS1R1
SCHEMBL3907168 0.89 UTS2R (0.45) UTS2RLMNAALDH1A1SMN1; SMN2HPGD
SCHEMBL3902328 0.88 UTS2R (0.46) UTS2RLMNAALDH1A1SMN1; SMN2HPGD
SCHEMBL3905781 0.85 UTS2R (0.50) UTS2RLMNAGPR139ALDH1A1SMN1; SMN2
SCHEMBL3904027 0.85 CTSS (0.56) SLC6A9P2RX7CTSS
SCHEMBL3901053 0.85 GPR139 (0.49) ITGB1ITGA4LMNAGPR139ALDH1A1
SCHEMBL8265761 0.84 ITGB1 (0.42) UTS2RITGB1ITGA4LMNAGPR139
SCHEMBL3907148 0.83 SLC6A9 (0.47) UTS2RLMNAALDH1A1SMN1; SMN2SLC6A9
SCHEMBL3906111 0.83 UTS2R (0.50) UTS2RITGB1ITGA4LMNAALDH1A1
SCHEMBL3901980 0.81 ALDH1A1 (0.47) UTS2RLMNAALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP claimed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS SLC18A2, SLC6A5, SLC1A2 UTS2R 3095/4885ITGB1 4719/4885ITGA4 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.